EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies

被引：0
|
作者：
Lillie, Thomas
Kichenadasse, Ganessan
Liu, Jia
Guerrero, Tatiana Hernandez
Calvo, Emiliano
Jakobsson, Haakan
Moreno, Victor
Gan, Hui Kong
Joyce, Peter
Hyland, Natalie
Giovannetti, Mara
Palmer, Tanya
McAlpine, Cheryl
Green, Daniel
Symeonides, Stefan N.
机构：
[1] Grey Wolf Therapeut, Abingdon, England
[2] Pty Ltd, Southern Oncol Clin Res Unit, Adelaide, SA, Australia
[3] St Vincents Hosp, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[4] START Barcelona, Barcelona, Spain
[5] START Madrid CIOCC, Ctr Integral Oncol Clara Campal, Madrid, Spain
[6] Alfred Hosp, Melbourne, Vic, Australia
[7] Univ Hosp Fdn Jimenez Diaz, START Madrid FJD, Med Oncol, Madrid, Spain
[8] Olivia Newton John Canc Wellness & Res Ctr, Victoria, NSW, Australia
[9] Univ Edinburgh, Edinburgh, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2589
引用
收藏
页数：1
相关论文
共 47 条
  • [1] GRWD5769: A FIRST-IN-CLASS INHIBITOR OF ERAP1, GENERATING NOVEL CANCER ANTIGENS TO DRIVE DE NOVO ANTI-TUMOR T CELL RESPONSES
    Joyce, Peter
    Leishman, Andrew
    Braun, Asolina
    Patel, Mitul
    Pinggera, Michael
    Sette, Jessica
    Anderton, Kate
    James, Edd
    Shunina, Valeriya
    Purcell, Anthony
    Ternette, Nicola
    Shiers, Jason
    Quibell, Martin
    Paes, Wayne
    McCarthy, Tom
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1175 - A1175
  • [2] GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses
    Leishman, Andrew
    Paes, Wayne
    Sparrow, Emma
    Ribeiro, Ana
    Cundell, Michael
    Aleksic, Milos
    Pinggera, Michael P.
    Sette, Jessica
    Anderton, Kate
    Ternette, Nicola
    Morgan, Juliet
    Shiers, Jason J.
    Quibell, Martin
    Joyce, Peter I.
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Proof-of-mechanism based on target engagement and modulation of gene expression following treatment with SY-1365, a first-in-class selective CDK7 inhibitor in Phase 1 patients with advanced cancer
    Juric, D.
    Papadopoulos, K. P.
    Tolcher, A.
    Do, K. T.
    Orlando, D.
    Zamboni, W.
    Hodgson, G.
    di Tomaso, E.
    Stephens, K.
    Roth, D.
    Shapiro, G. I.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E19 - E19
  • [4] Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors
    Aoyama, T.
    Fasolo, A.
    Stathis, A.
    Sessa, C.
    Hollebecque, A.
    Soria, J. C.
    Pastorino, A.
    Sobrero, A. S. Alberto
    Van Laethem, J. L.
    Saito, K.
    Yoshidas, K.
    Winkler, R.
    Benedetti, F.
    Gianni, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S117 - S118
  • [5] Phase 1 Study of first-in-class dUTPase inhibitor, TAS-114 in combination with capecitabine in patients with advanced solid tumors
    LoRusso, P.
    Miller, K.
    Shields, A.
    Saito, K.
    Yoshida, K.
    Aoyama, T.
    Winkler, R.
    Benedetti, F.
    Lenz, H. J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S119 - S119
  • [6] CHK-336, A FIRST-IN-CLASS ORALLY ADMINISTERED LDH INHIBITOR: SAFETY, PK AND TARGET ENGAGEMENT IN A FIRST-IN-HUMAN PHASE 1 HEALTHY VOLUNTEER STUDY
    Tong, Vincent
    Schwartz, Brian
    Lam, Chun
    Knight, John
    Fargue, Sonia
    Wagner, David A.
    Wong, Harvey
    Wang, Lei
    Kocinsky, Hetal
    Fauvelle, Valerie
    King, Andrew
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I11 - I11
  • [7] A phase 1 dose escalation study of BBI6087 a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies
    Langleben, Adrian
    Supko, Jeffrey G.
    Hotte, Sebastien
    Lorusso, Patricia
    Miller, Wilson H.
    Hurtubise, Annie
    Leggett, David S.
    Li, Wei
    Borodyanski, Laura
    Li, Chiang J.
    CANCER RESEARCH, 2010, 70
  • [8] Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
    Rodon, Jordi
    Argiles, Guillem
    Connolly, Roisin M.
    Vaishampayan, Ulka
    de Jonge, Maja
    Garralda, Elena
    Giannakis, Marios
    Smith, David C.
    Dobson, Jason R.
    McLaughlin, Margaret E.
    Seroutou, Abdelkader
    Ji, Yan
    Morawiak, Jennifer
    Moody, Susan E.
    Janku, Filip
    BRITISH JOURNAL OF CANCER, 2021, 125 (01) : 28 - 37
  • [9] A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies
    Sharp, Adam
    Williams, Anja
    Blagden, Sarah Patricia
    Plummer, Elizabeth Ruth
    Hochhauser, Daniel
    Krebs, Matthew
    Pacey, Simon
    Evans, T. R. Jeffry
    Whelan, Sarah
    Nandakumar, Srinand
    Rogers, Seema
    Jameson, Katherine L.
    Basile, Frank G.
    De Bono, Johann S.
    Arkenau, Hendrik-Tobias
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
    Jordi Rodon
    Guillem Argilés
    Roisin M. Connolly
    Ulka Vaishampayan
    Maja de Jonge
    Elena Garralda
    Marios Giannakis
    David C. Smith
    Jason R. Dobson
    Margaret E. McLaughlin
    Abdelkader Seroutou
    Yan Ji
    Jennifer Morawiak
    Susan E. Moody
    Filip Janku
    British Journal of Cancer, 2021, 125 : 28 - 37
12345